This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Feb;59(2):301-2.

doi: 10.1016/j.eururo.2010.11.009.

Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

Edward N Rampersaud Jr¹, Arie S Belldegrun

Affiliations

PMID: 21414876
DOI: 10.1016/j.eururo.2010.11.009

Comment

Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

Edward N Rampersaud Jr et al. Eur Urol. 2011 Feb.

. 2011 Feb;59(2):301-2.

doi: 10.1016/j.eururo.2010.11.009.

Authors

Edward N Rampersaud Jr¹, Arie S Belldegrun

Affiliation

¹ Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

PMID: 21414876
DOI: 10.1016/j.eururo.2010.11.009

No abstract available

PubMed Disclaimer

Comment on

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Addeo R, et al. J Clin Oncol. 2010 Feb 1;28(4):543-8. doi: 10.1200/JCO.2008.20.8199. Epub 2009 Oct 19. J Clin Oncol. 2010. PMID: 19841330 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science